Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.54 |
| ▸ | JAK1 | P23458 | 11/20 | 0.54 |
| ▸ | TYK2 | P29597 | 11/20 | 0.54 |
| ▸ | JAK3 | P52333 | 11/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613448 | 0.86 | JAK2 (0.55) | JAK2JAK1TYK2JAK3IKBKE | |
| SCHEMBL13613459 | 0.81 | JAK2 (0.53) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606583 | 0.81 | JAK2 (0.63) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613447 | 0.81 | JAK2 (0.54) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613449 | 0.80 | JAK2 (0.66) | JAK2JAK1TYK2JAK3NPC1 | |
| SCHEMBL14468618 | 0.79 | JAK2 (0.51) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613456 | 0.78 | CHEK1 (0.57) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613718 | 0.78 | JAK2 (0.76) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14468619 | 0.78 | JAK2 (0.49) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606562 | 0.77 | JAK2 (0.68) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | JAK2 1101/4885JAK1 1726/4885TYK2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.